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Abstract Severe pulmonary infection or vigorous cyclic de-
formation of the alveolar epithelial type I (AT I) cells by me-
chanical ventilation leads to massive extracellular ATP re-
lease. High levels of extracellular ATP saturate the ATP hy-
drolysis enzymes CD39 and CD73 resulting in persistent high
ATP levels despite the conversion to adenosine. Above a cer-
tain level, extracellular ATP molecules act as danger-associat-
ed molecular patterns (DAMPs) and activate the pro-
inflammatory response of the innate immunity through
purinergic receptors on the surface of the immune cells.
This results in lung tissue inflammation, capillary leakage,
interstitial and alveolar oedema and lung injury reducing the
production of surfactant by the damaged AT II cells and
deactivating the surfactant function by the concomitant ex-
travasated serum proteins through capillary leakage followed
by a substantial increase in alveolar surface tension and al-
veolar collapse. The resulting inhomogeneous ventilation of
the lungs is an important mechanism in the development of
ventilation-induced lung injury. The high levels of extracel-
lular ATP and the upregulation of ecto-enzymes and soluble
enzymes that hydrolyse ATP to adenosine (CD39 and
CD73) increase the extracellular adenosine levels that inhibit
the innate and adaptive immune responses rendering the host
susceptible to infection by invading microorganisms.
Moreover, high levels of extracellular adenosine increase
the expression, the production and the activation of pro-
fibrotic proteins (such as TGF-β, α-SMA, etc.) followed
by the establishment of lung fibrosis.
Keywords Extracellular ATP . Ventilation-induced lung
injury . Diffuse alveolar damage . Purinergic signalling .
CD39 . CD73
Introduction
Diffuse lung injury can be triggered by several experimental
conditions, amongst others: Severe pulmonary infection or
extrapulmonary infection leads to acute pulmonary distress
syndrome (ARDS) [1–5]; Mechanical ventilation with high
inspiratory pressures and high tidal volumes of >30 ml/kg
ideal body weight in animals with healthy lungs causes inter-
stitial and alveolar oedema and diffuse lung injury (ventila-
tion-induced lung injury (VILI)) [6]; And mechanical ventila-
tion in surfactant-deactivated animals causes VILI even with
low tidal volume (LVT) of 6 ml/kg [7]. On the other hand,
experimental mechanical ventilation with airway pressure re-
lease ventilation (APRV) with relatively long inspiration time
and very short pressure release period may protect the lungs
[7–14].
It is clear that lung infection results in pro-inflammatory
immune response. In addition, there is a general agreement
that ventilation of inhomogeneous lung tissue and/or with a
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high tidal volume triggers a pro-inflammatory response
[15–19]. The corollary to this is that reduction of tidal volume
and return to homogeneous ventilation will reduce (but not
prevent) this pro-inflammatory response [19]. However, the
exact mechanism of ventilation-induced pro-inflammatory re-
sponse that leads to VILI is still not fully understood [15–18].
Moreover, the combination of all mechanical breath parame-
ters (known as the mechanical breath profile (MBP) airway
pressures, volumes, flow rates and the duration at both inspi-
ration and expiration) applied with each breath, which injure
or protect the lung, is still not known.
In this review, we have searched the literature thoroughly to
identify the (missing) link between the MBP, alveolar me-
chanics (i.e. the dynamic change in alveolar size and shape
during tidal ventilation) and the inflammatory response that
causes VILI.
Alveolar mechanics, alveolar surface tension
and VILI
Conventional mechanical ventilator settings consist of a static
and a dynamic component. The static component is a contin-
uous pressure or stress applied during both the inspiration and
expiration and results in a static volume change or static strain.
Strain is defined as a change in volume normalised by the
original volume. The static stress and strain are referred to as
positive end-expiratory pressure (PEEP) and the change in
end-expiratory lung volume (EELV) normalised by the func-
tional residual capacity (FRC) of the lungs, respectively. If the
applied PEEP is zero, the EELVequals the FRC. Thus, EELV
equals FRC plus PEEP volume. The dynamic component is
the strain (i.e. tidal volume (VT) normalised by FRC or EELV)
inflicted by the cyclic stress, i.e. the inspiratory pressure [20].
Cyclic lung volume change with high energy load causes
VILI in healthy lungs
Protti et al. determined the mean value of the global energy
load calculated from the mean inspiratory capacity by means
of whole-lung CTscan in 76 pigs with healthy lungs [6].Mean
inspiratory capacity was defined as the mean value of total
lung capacity (TLC) measured at 45 cm H2O airway pressure
minus the FRC measured at 0 cm H2O airway pressure. The
global energy load during conventional mechanical ventila-
tion comprised a static component due to lung volume caused
by the applied PEEP and a dynamic component due to the
applied inspiratory pressure. The lower and upper limit of
the applied global energy load was set at the value of mean
global energy load ±2SD (equivalent to an inspiratory capac-
ity range of 30.9–59.7 ml/kg ideal bodyweight). Then, the
animals were subjected to different levels of PEEP and inspi-
ratory pressures. When the mean global energy load did not
exceed its lower limit, lung damage was not observed and
only 1 of the 29 experimental animals did not survive the
experiment. In contrast, when the mean global energy load
exceeded the lower limit of the global energy load, lung injury,
pro-inflammatory cytokine production and death were ob-
served in 26 of the 47 experimental animals. In these cases,
lung damage was associated with high dynamic energy load
rather than high static energy load [6]. In addition, the rate of
the applied strain was associated with ventilation-induced
lung oedema and lung injury [21].
In surfactant-deactivated lungs cyclic lung volume change
causes VILI even with low energy load
Remarkably, the threshold of the energy load above which
lung damage occurred in healthy pig lungs was quite high
(equivalent to a mean VT of >30 ml/kg ideal body weight)
[6], whereas a VT of 6 ml/kg is already injurious in the
surfactant-deactivated lungs [11]. This difference is clearly
illustrated in the following experiment. In anaesthetised me-
chanically ventilated pigs, normal subpleural alveoli were
filmed in real time using in vivo video microscopy. This study
discovered that there was very little change in alveolar size in
healthy lungs when ventilated with LVT (6 ml/kg ideal body
weight) or with HVT (12 or 15 ml/kg ideal body weight). In
contrast, after surfactant deactivation with a detergent as a
model of ARDS, the alveoli became unstable: Many alveoli
collapsed at the end of the expiration, and some of these col-
lapsed alveoli were recruited during inspiration irrespective of
the magnitude of the tidal volume. Alveoli that remained open
at the end of the expiration became over-distended during the
inspiration resulting in an inhomogeneous ventilation pattern
in the lungs [22].
Stabilization of the alveoli prevents VILI
Bachofen and Schürch demonstrated with scanning electron
micrographs that surfactant deactivation and consequently in-
creased surface tension in the alveoli in detergent rinsed lungs
increase the alveolar duct surface area at the expense of alve-
olar surface area as compared to normal lungs. The increased
alveolar duct size is accompanied by a decrease in the alveolar
diameter perpendicular to the axis of the alveolar ducts (alve-
olar wall compression) and by an increase in the alveolar
diameter parallel to the axis of the alveolar ducts. Therefore,
surfactant deactivation is accompanied by alveolar wall
stretching [23]. This finding was confirmed in an experiment
in anaesthetised rats by the group of Nieman. After en bloc
excision of the lungs, one of the lungs was clamped and fixed
in formalin at peak inspiration pressure and the other at end
expiration pressure for histologic analysis. In this way, they
were able to visualise the effect of surfactant deactivation
(Tween-induced ARDS model) and mechanical ventilator
Purinergic Signalling
settings on alveolar duct microstrain and the distribution of
inspired air between the alveolar ducts and the alveoli (Fig. 1)
[8]. Microstrain was calculated as the change in length of the
alveolar ducts between inspiration and expiration normalised
by their original length. As the increase in the alveolar duct
size after surfactant deactivation is accompanied by alveolar
wall stretching parallel to the axis of the alveolar ducts [23],
alveolar duct microstrain is likely to be proportional to the
alveolar wall stretching and alveolar wall strain.
Four ventilation strategies were tested by this group [8]:
LVT plus two levels of PEEP (5 and 16 cm H2O) and APRV
with the expiratory termination set at either an end-expiratory
flow (EEF) of 10% (APRV 10%) of the peak-expiratory flow
(PEF) or an EEF of 75% of the PEF (APRV 75%) [24, 25]; the
higher the EEF/PEF ratio (i.e. 75% as compared with 10%),
the shorter the expiratory duration (see Table 1 for the MBP of
the set ventilator modes). Previous studies have shown that
APRV 75% stabilises alveoli preventing alveolar collapse dur-
ing expiration, whereas an APRV 10% extends the duration of
expiration resulting in alveolar collapse [12, 24, 25]. This
study demonstrated that APRV 10% caused high microstrain
and redistribution of air towards the alveolar ducts as com-
pared with APRV 75%, which resulted in almost normal dis-
tribution of air (Fig. 1). The order of ventilation strategies that
caused the most to the least redistribution of inspired air into
alveolar ducts (inspiratory ratio Ca/Aa in Table 2) and
microstrain was as follows: APRV 10%, PEEP 5, PEEP 16,
APRV 75% and control (Table 2). Obviously, the least injuri-
ous ventilator settings are those that mimic the microstrain and
air redistribution levels in ventilated healthy lungs with intact
surfactant function (control in Fig. 1). APRV 75% resulted in
near normal microstrain and alveolar air distribution, which
was very similar to that measured in normal lungs, even
though APRV 75% was in a Tween-induced ARDS model
(Fig. 1, APRV 75% and Table 2). In this high surface tension
ARDS model, the lower the PEEP (PEEP 5 vs PEEP 16) and
the longer the expiratory duration (10 vs 75%), the worse the
microstrain and alveolar air distribution (Fig. 1, Table 2). This
research group hypothesised that the mechanism by which
APRV 75% was so effective at normalizing microstrain and
alveolar air distribution was as follows: The extended time at
inspiration (achieved by applying continuous positive airway
Fig. 1 Photomicrographs of rat lungs. After en bloc excision of the lungs,
one of the lungs was clamped and fixed in formalin at peak inspiration
pressure and the other at end expiration pressure for histologic analysis.
The respiratory bronchiole, alveolar ducts and alveolar sacs are green; the
alveoli are lilac; and the alveolar walls are magenta. Healthy lungs
ventilated with controlled continuous mandatory ventilation (CMV) with
low tidal volume (≤6 ml/kg ideal body weight) and 5 cm H2O PEEP
(control). APRV: surfactant-deactivated lungs with intratracheal instilla-
tion of a detergent ventilated with Tlow being interrupted when the end-
expiratory flow (EEF) reached 75% (APRV 75%) or 10% (APRV 10%)
of the peak expiratory flow (PEF). (PEEP 5) Surfactant-deactivated lungs
ventilated with the same settings as ‘control’ or with PEEP 16 cm H2O
(PEEP 16) (see Table 1 for the mechanical breath profile data). Note that
the highest alveolar duct surface area is reached during inspiration in
APRV 10% followed by PEEP 5; the lowest alveolar duct surface area
is observed in the control group. The highest alveolar stability (the
smallest difference in alveolar duct surface area between inspiration and
expiration) with the lowest microstrain is reached in healthy lungs
(control) followed by APRV 75%. The lowest alveolar stability and the
highest microstrain are seen in APRV 10% and PEEP 5. Microstrain is
calculated as the change in length of the alveolar ducts between inspira-
tion and expiration normalised by their original length. The difference
between the control group and PEEP 5 is exclusively attributed to the
surfactant function. APRV can either significantly increase (APRV 10%)
or decrease (APRV 75%) the microstrain and the redistribution of air
towards the alveolar ducts. Figure from Kollisch-Singule et al. [8] with
permission
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pressure) recruited almost all alveoli, and the very short time
at expiration prevented these newly recruited alveoli from
collapsing. In contrast, APRV 10% resulted in the worst
microstrain and air distribution since the high pressure and
extended inspiratory duration opened alveoli but the exces-
sively long expiratory duration allowed time for all of the
newly opened alveoli to collapse (Fig. 1) [8]. One mechanism
of this lung protection was that APRV 75% preserved surfac-
tant function, measured by increased concentrations of surfac-
tant protein-A (SP-A) and SP-B in the bronchoalveolar lavage
fluid, as compared to controlled CMV with a VT of 10 ml/kg
ideal body weight [10]. Apparently, redistribution of air to-
wards the alveolar ducts and the increase in microstrain in
controlled CMV deplete pulmonary surfactant. This supports
earlier works showing that mechanical ventilation can impair
pulmonary surfactant function [26, 27].
The protective effect of APRV 75% (APRV settings: Phigh
16–22 cm H2O, Thigh 4.5 s, Plow 0 cm H2O) on lung tissue
injury was also demonstrated in anaesthetised pigs with
extrapulmonary ARDS. In contrast to LVT controlled CMV
(VT 6 ml/kg ideal body weight, RR 55/min, I/E 1:2, FiO2
21% PEEP 5 cm H2O and guided by the ARDSnet protocol
[28]), APRV 75%was capable of preventing the development
of DAD while maintaining lung elastance low, despite the fact
that APRV 75% generated similar transpulmonary pressure
compared to LVT [11].
The characteristics of lung tissue damage in ARDS
and VILI are pointing at the activation of the innate
immune system
The histopathology of VILI is referred to as diffuse alveolar
damage (DAD) and is very similar to the histopathology as-
sociated with experimental ARDS. Reportedly, in contrast to
the animal models of ARDS [29, 30], histopathology of DAD
is found in only one third to half of patients with clinical
diagnosis of ARDS [31–33]. ARDS is caused by multiple
primary disease conditions such as sepsis, haemorrhagic
shock and pneumonia, and these patients will require
Table 1 Mechanical breath
profile (MBP) of the set ventilator
modes
MBP Ventilator mode
Controla APRV 75% PEEP 16 PEEP 5 APRV 10%
Plateau pressure (cm H2O) N/A 36.7 31 22.8 36.7
Tidal volume (ml/kg) 6 10.9 5.68 5.34 17
PEEP (cm H2O) 5 N/A 16 5 N/A
Respiratory frequency (min−1) 55 29.2 55 55 26.9
Inspiratory time or Thigh (s) 0.73 1.9–2.0 0.73 0.73 1.9–2.0
Expiratory time or Tlow (s) 0.36 0.04–0.08 0.36 0.36 0.22–0.26
The columns are sorted according to increasing microstrain values as shown in Table 2. APRV: Tlow being
interrupted when the end-expiration flow (EEF) reached 75% (APRV 75%) or 10% (APRV 10%) of the peak
expiratory flow (PEF)
a The values in the control column are set values of the mechanical ventilator. The values in columns of the
remaining ventilator modes are measured MBP values [12]
Table 2 Microstrain and
redistribution of the inspired air
from the alveoli towards the
alveolar ducts (ratio Ca/Aa)
Effects of MBP on the lung tissue Ventilatory mode
Control APRV 75% PEEP 16 PEEP 5 APRV 10%
Microstrain 0.137 0.202 0.231 0.336 0.394
Ratio Ca/Aa (inspiration) 0.33 0.65 0.81 0.9* 2.07*
Ratio Ca/Aa (expiration) 0.35 0.51 0.79* 0.6 1.32*
The columns are sorted according to increasing microstrain values. Microstrain is calculated as the change in
length of the alveolar ducts between inspiration and expiration normalised by their original length. The lowest
microstrain is observed in the control group and increasing in APRV 75%, PEEP 16, PEEP 5 and APRV 10%,
respectively. Table based on Table 2 in the article by Kollisch-Singule, et al. 2014 [8] with permission
Ca alveolar duct surface area, Aa alveolar surface area, APRV 10% the expiratory termination set at an end-
expiratory flow (EEF) of 10% of the of the peak expiratory flow (PEF), APRV 75% the expiratory termination
set at an EEF of 75% of the PEF
*p < 0.05 vs control
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mechanical ventilation. If set improperly, mechanical ventila-
tion can cause a secondary VILI, which will aggravate the
DAD caused by the primary disease. There are three distinc-
tive stages in the histopathology of DAD [34, 35]: The early
exudative stage initiates after 12 to 24 h with declining fre-
quency to almost zero after 4 weeks, the late proliferative
stage with increasing frequency reaching almost 100% after
4 weeks and the fibrotic stage after 1 week increasing gradu-
ally reaching about 60% after 4 weeks. In the first 12 to 24 h:
capillary congestion, interstitial and alveolar oedema [34].
The oedema results mainly from capillary leakage of fluid
and proteins [36]. After 24 h, the characteristic histopathology
is the presence of hyaline membranes. These membranes are
found adjacent to the alveolar ducts and alveolar walls
consisting of eosinophilic structures with cell debris, plasma
proteins and surfactant degradation products. The alveolar
walls are oedematous and thickened and filled with myxoid
matrix comprising fibroblasts and myofibroblasts (fibroblasts
phenotype containing alpha smooth muscle actins (α-SMA)),
slight infiltration of the interstitial space with lymphocytes,
plasma cells and macrophages. A significant proportion of
the alveolar epithelial type I (AT I) cells and a small proportion
of the AT II cells are damaged and lost leaving the alveolar
membranes exposed. This means that the physical barrier
against pathogens—a component of the innate immunity—is
disrupted. Self-renewal of the epithelium (AT I and AT II
cells) is performed by the AT II cells [37] and is accompanied
by AT II hyperplasia which appears in 3 to 6 days. Mild
endothelial injury is also reported [34]. In the proliferative
phase of DAD, hyaline membranes are no longer prominent.
The characteristic histopathology in the interstitium is the pro-
liferation of fibroblasts, myofibroblasts and AT II cells mixed
with occasional inflammatory cells. This granulation tissue
breaks through the basement membrane into the alveolar
spaces. The proliferating AT II cells show metaplasia resem-
bling squamous cell carcinoma [34]. These AT II cells migrate
over the surface of the alveolar granulation tissue and the
intraalveolar exudate establishing the so-called fibrosis by ac-
cretion [38]. In addition, fibrosis is also formed by collagen
deposits in the process of the organization of the interstitial
oedema [34]. These processes and the increase in the surface
tension by the deficient surfactant production and function in
the inflammatory process lead to the collapse of the alveoli,
size reduction of the remaining open alveoli and dilated alve-
olar ducts [23, 38]. After 3 to 4 weeks, granulation tissue of
the fibrotic process dominates the lung histology. Enlarged
airspaces—most likely in the alveolar ducts [8, 23, 38]—are
outlined by collapsed alveoli with thickened alveolar walls
[34]. The percentage of fibrosis and the amount of interstitial
tissue increase over time [39]. In addition, the normally non-
muscular small arteries are being muscularised and muscular
arteries show intimal and subintimal fibrous thickening. This
development may end in pulmonary hypertension [34].
Surfactant metabolism and physiological purinergic
signalling in the lungs are required for the release
of surfactant by the AT II cells
Since surfactant dysfunction plays a crucial role in the devel-
opment of DAD, the regulation of metabolism and secretion
of surfactant may contribute to the pathogenesis of DAD.
Surfactant lipids and surfactant proteins are synthetised
through different pathways by the AT II cells in the alveolar
walls. Surfactant protein (SP-A, SP-B, SP-C and SP-D) syn-
thesis starts in the endoplasmic reticulum (ER). The surfactant
protein molecules are transported from the ER to the Golgi
complex. SP-A and SP-D are excreted directly to the extracel-
lular space [40]. SP-A and SP-D (both are hydrophilic protein
molecules) belong to the collectins, a family of calcium-
dependent sugar-binding proteins (lectins) containing
collagen-like sequences and carbohydrate recognition do-
mains (CRDs). Collectins are soluble pattern recognition re-
ceptors (PRRs, components of the innate immunity) that can
identify pathogen-associated molecular patterns (PAMPs) and
several danger-associated molecular patterns (DAMPs) [41,
42]. SP-B and SP-C plus ATP-binding cassette subfamily A
member 3 (ABCA3, a surfactant lipid transporter) are
transported from the Golgi complex to the multivesicular bod-
ies (MVBs). Fusion of MVBs and the lamellar bodies (LBs)
leads to the proteolytic process of SP-B and SP-C to the ma-
ture form. The surfactant lipids are produced in the ER as well
but transported directly to the LBs by means of the lipid trans-
porter ABCA3. The hydrophobic proteins SP-B and SP-C are
essential in the packing process of surfactant lipid molecules
in the LBs [40].
Under physiological conditions, mammalian cells contain
high concentrations of ATP (5 to 8 mM) and ADP [43]. In the
extracellular space, ATP can be detected in much lower
(nanomolar) concentrations around resting cells [44]. Certain
conditions may cause the release of ATP. In cell stress condi-
tions such as an infection, ATP can be released in a controlled
manner through pannexin hemichannels (mainly Panx1) [45,
46], connexin channels (mainly Cx43) [47, 48], certain chlo-
ride channels (maxi-anion channels, volume-regulated anion
channels (VRAC), cystic fibrosis transmembrane conduc-
tance regulator (CFTR), chloride channel (ClC) family and
calcium-activated chloride channel (CACC)) [49] and P2X7
ATP receptors (P2X7Rs) [50, 51] to >1000-fold of the resting
state levels to micromolar concentrations. In cell ischemia and
cell necrosis, ATP is released massively and uncontrolled [43,
52, 53]. Infection (such as in ARDS due to infectious agents)
induces the release of extracellular ATP by many inflamma-
tory cells and tissue cells (such as the AT I cells) [43, 52, 53].
In non-infectious circumstances such as physiological me-
chanical deformation (stretch or compression during breathing
or mechanical ventilation) of the AT I cells stimulates the
P2X7Rs followed by the controlled release of ATP molecules
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through the P2X7R channel into the extracellular space
(Fig. 2) [54, 57].
Recently, using real-time luciferin-luciferase biolumi-
nescence imaging coupled with simultaneous infrared dif-
ferential interference contrast imaging, Furuya et al. were
able to produce real-time imaging of inflation-induced
ATP release in the ex vivo rat lung. They observed that
lung inflation induces ATP release into alveolar spaces
and into pulmonary blood capillaries [58]. In this way,
extracellular purine nucleotides (such as ATP) play the
key role in the extracellular signalling (purinergic signal-
ling) of many biological processes and can activate
purinergic receptors—for example, the P2Y2R—on the
cell membranes [52]. The extracellular ATP originating
from the AT I cells, released through the P2X7Rs by me-
chanical deformation, activates the P2Y2Rs on the surface
of the AT II cells. The P2Y2R is a metabotropic G
protein-coupled ATP receptor (GPCR). Activation of the
P2Y2R by ATP results in the release of diacylglycerol
(DAG) and inositol triphosphate (IP3) into the cytoplasm.
DAG activates the enzyme protein kinase C (PKC) that
promotes the fusion of LBs with the cell membrane
(Fig. 2). Cytoplasmic IP3 results in the release of intracel-
lular Ca2+ by stores that are sensitive to IP3 and Ca
2+
entry from the extracellular space through several path-
ways (TRPV2 and STIM1/Orai1). The increased cytoplas-
mic Ca2+ level also promotes the fusion of the LBs with
the cell membrane of the AT II cells and creates a fusion
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Fig. 2 Schematic presentation of the fusion-activated Ca2+ entry
(FACE). AT I cells release ATP to the extracellular space through the
P2X7R (ATP receptor that can function as an ATP channel) provoked
by mechanical deformation (compression or stretching) [43, 54–56]. The
extracellular ATP activates the P2Y2Rs on the surface of the AT II cells in
a paracrine manner. The G protein-coupled P2Y2 ATP receptor releases
DAG and IP3 into the cytoplasm. DAG release leads to the activation of
PKC-dependent pathway of fusion of LBs with the cell membrane. IP3
release results in the release of intracellular Ca2+ by stores that are sensi-
tive to IP3 and Ca
2+ entry from the extracellular space through several
pathways (TRPV2 and STIM1/Orai1). Increased cytoplasmic Ca2+ level
also promotes the fusion of the LBs with the cell membrane of the AT II
cells. These two processes create a fusion pore causing the P2X4 ATP
receptors in the membrane of the LBs to be exposed to extracellular ATP.
Activation of these P2X4Rs by extracellular ATP strongly increases the
local Ca2+ concentration to a much higher level around the membrane of
the fused vesicles (FACE). FACE promotes a significant expansion of the
fusion pore resulting in surfactant release by the AT II cells (LBs
unpacking) and is accompanied by the FACE-induced cations and water
migration from the alveolar space to the subepithelial interstitium.
Clearance of the ATP molecules from the extracellular space occurs
through the stepwise conversion by ecto-enzymes or by soluble extracel-
lular enzymes (CD39 and CD73) to adenosine (ADO). ADO is returned
to the cytoplasm through ENTs or CNTs and converted by ADA to ino-
sine in the cytoplasm or converted by soluble ADA in the extracellular
space. AT I alveolar epithelial type I cell, AT II alveolar epithelial type II
cell, ER endoplasmic reticulum, LB lamellar body, DAG diacylglycerol,
PKC protein kinase C, IP3 inositol triphosphate, IP3R inositol triphos-
phate receptor, a membrane bound glycoprotein complex functioning as a
Ca2+ channel sensitive to activation by inositol triphosphate, TRPV2 tran-
sient receptor potential cation channel subfamily V member 2, a non-
selective cation channel, STIM1 stromal interactionmolecule 1, a calcium
sensor, Orai1 calcium release-activated calcium channel protein 1, a cal-
cium selective ion channel, CD39 nucleoside triphosphate
diphosphohydrolase 1 (NTPD1), NPP nucleotide pyrophosphatase/phos-
phodiesterase,CD73 5′-nucleotidase (5′-NT), ADA adenosine deaminase,
ENTs equilibrative nucleoside transporters 1 and 2, CNTs concentrative
nucleoside transporters 1 and 2
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pore causing the P2X4Rs in the membrane of the LBs to
be exposed to the extracellular ATP (Fig. 2). Activation of
these P2X4Rs by extracellular ATP strongly increases the
local Ca2+ concentration around the membrane of the
fused vesicles to a much higher level (Fig. 2). This pro-
cess—referred to as ‘fusion-activated’ Ca2+ entry
(FACE)—promotes a significant expansion of the fusion
pore resulting in surfactant release by the AT II cells (LBs
unpacking). Thus, the AT I cells induce the unpacking of
LBs by the AT II cells in a paracrine manner (Fig. 2) [54,
55, 59, 60]. In addition, at a higher degree of stretch of
the AT II in vitro (probably comparable to a deep sigh),
ATP molecules can be released to the extracellular space
and induce LBs unpacking in an autocrine manner [57].
FACE drives a trans-epithelial current of Na+ and Ca2+
from the alveolar lumen through the P2X4R in the fused LB
membranes and the cytoplasm to the subepithelial intersti-
tium. This is followed by a passive water resorption from
the alveolar space to the subepithelial interstitial space. In
other words, extracellular ATP induces extracellular excretion
of surfactant to the alveolar space and reduces the quantity of
fluid in the alveolar liquid lining maximizing the reduction of
the surface tension of the alveoli (Fig. 2) [56].
The P2X7Rs that release the extracellular ATP molecules
are not subject to a refractory period during mechanical defor-
mation [57]. In rat glomerular mesangial cell culture, 72% of
the cells show an increase in Ca2+ levels during a 2-min stim-
ulus with 100 μMATP through the P2Y2Rs. In contrast to the
p2X7Rs, the P2Y2Rs start to desensitise within 1 min, and the
sensitivity to stimuli reaches its minimum within 2 to 4 min
[61, 62]. After a recovery period of another 4 min, only 38%
of the cells respond to a second stimulus. The response fol-
lowing the second stimulus is much weaker than the first
stimulus [62]. The P2X4Rs become desensitised faster than
the P2Y2Rs (within a few seconds after a stimulus with ATP),
and the sensitivity to stimuli reaches its minimum after 30 to
60 s [63, 64]. Therefore, vigorous mechanical deformation of
the AT I cells may cause excessive extracellular release of
ATP but is unlikely to cause massive LBs unpacking.
Clearance of the ATP and ADP molecules from the extra-
cellular space is performed through the stepwise conversion of
extracellular ATP molecules by ecto-enzymes or by soluble
extracellular enzymes to adenosine (Fig. 2). These enzymes
comprise nucleoside triphosphate diphosphohydrolase 1
(NTPD1 or CD39, conversion of ATP to ADP and ADP to
AMP), nucleotide pyrophosphatase/phosphodiesterase (NPP,
conversion of ATP to AMP) and 5′-nucleotidase (5′-NT or
CD73, conversion of AMP to adenosine). Then, adenosine
is converted by soluble extracellular adenosine deaminase
(ADA) to inosine or is returned to the cytoplasm of the cells
through the equilibrative nucleoside transporters (ENT1 and
ENT2) and concentrative nucleoside transporters (CNT1 and
CNT2). Inside the cells, adenosine is being further processed
by ADA and purine nucleoside phosphorylase (PNP) to ino-
sine and hypoxanthine, respectively, and by adenosine kinase
(ADK) to AMP [43, 52, 53, 65]. Under normal conditions,
extracellular levels of ATP are kept low by the controlled
release of these nucleotides and by the clearance of these
nucleotides by the soluble or ecto-enzymes CD39, NPP and
CD73 (Fig. 2) [43, 52, 53].
There are several mechanisms to clear surfactant from the
alveolar space: (1) a small fraction of the surfactant lipids is
squeezed out during the respiratory cycles to the bronchiole
[66]; (2) degraded surfactant lipids are phagocytised by mac-
rophages which is depending on the cytokine granulocyte mac-
rophage colony-stimulating factor (GM-CSF) signalling
through the macrophages GM-CSF receptor CSF2R [40]; (3)
SP-D and the G protein-coupled receptor 116 (GPCR116) are
involved in the reuptake of surfactant into the AT II cells and
the MVBs for recycling purposes. Some of the lipid molecules
are taken up by the lysosomes for further degradation [40]; (4)
phosphates from degraded lipids are returned to the AT II cells
by means of the sodium-dependent phosphate transport protein
2B (coded by the transcription factor SLC34a2) [40].
Obviously, the loss of the alveolar epithelial cells in DAD
results in reduced LB surfactant stores and reduced surfactant
production. Moreover, surfactant production can be decreased
by pulmonary infection [67] and by hyperoxia (ventilation
with air with 98% oxygen content) [68]. Surfactant deactiva-
tion by extravasated serum proteins [69] and the conversion of
the active to the non-active surfactant subfraction contribute to
further surfactant impairment [27]. Loss of surfactant produc-
tion is accompanied by the deficiency of SP-A and SP-D
molecules. As discussed above, SP-A and SP-D are soluble
PRRs; they are important components of the innate immunity
for the recognition of PAMPs and several DAMPs [41, 42].
Therefore, deficiency of SP-A and SP-D weakens the immune
defence against invading pathogens.
Prolonged induced excess of purinergic signalling
leads to pro-inflammatory immune response,
immunodepression and lung fibrosis
The effects of purinergic signalling through the binding of
nucleotides (ATP, ADP, UTP and UDP) and nucleoside
(adenosine) to different receptors on the innate and adaptive
immune system are presented in Table 3. This table clarifies
the importance of purinergic signalling in the regulation of
both pro-inflammatory and anti-inflammatory responses of
the immune system and the fibrotic process in the tissues.
Purinergic regulation of the pro-inflammatory responses
Although many ATP receptors play a role in the activation of
the pro-inflammatory immune response (Table 3), activated
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Purinergic Signalling
P2X7Rs are important initiators of the pro-inflammatory re-
sponse by the innate immunity [43, 53, 210]. P2X7R is an
ATP receptor and an intrinsic cation channel, but here, the
P2X7R serves as an ATP receptor initiating intracellular trans-
duction. Furthermore, the P2X7Rs have a low affinity for ATP
molecules. They are activated only when the concentration of
extracellular ATP is quite high reaching millimolar concentra-
tions [70, 211], for example, during a severe inflammation
leading to ARDS and/or vigorous mechanical deformation
of the AT I cells (Fig. 3). In these conditions with high levels
of extracellular ATP, the P2X7R does not appear to exhibit
desensitization [64, 215]. Consequently, high levels of extra-
cellular ATP molecules continuously act as DAMPs and acti-
vate the immune system [43, 53, 70]. In case of massive re-
lease, ATP may saturate the ATP hydrolysis enzymes CD39
and CD73 causing persistent high ATP levels despite the con-
version to adenosine. The resulting pro-inflammatory immune
response causes damage to the lung tissue and ends in DAD.
Interstitial and alveolar oedema are the result of capillary leak-
age due to the pro-inflammatory response in the early exuda-
tive stage of DAD [34, 36].
Reportedly, another mechanism of the development of alveo-
lar oedema in ARDS after influenza virus infection is proposed
[216, 217]: influenza virus-induced disruption of the tight junc-
tions between the alveolar epithelia cells and direct inhibition of
amiloride-sensitive epithelial sodium channels (ENaCs) [217].
The devastation of the normal alveolar histology in DAD is such
that the tight junctions between the epithelial cells are indeed
disrupted. But massive ATP release by alveolar epithelial cells
after H1N1 influenza A virus (IAV) [218, 219], respiratory syn-
cytial virus (RSV) infection [220, 221] and parainfluenza infec-
tion virus infection [222] as detected by increased ATP in bron-
choalveolar lavage fluid (BALF) have also been reported.
Consequently, activation of P2X7Rs in epithelial cells and mac-
rophages after a viral infection results in a pro-inflammatory
response of the innate immune system [151] (Table 3, rows
63–66 and row 76) [162–164, 174] and lung tissue injury.
Therefore, it is extremely difficult to assess whether the
influenza-induced ENaC inhibition in the lung tissue plays a
significant role in the development of alveolar oedema in
ARDS with profound capillary leakage as part of the pro-
inflammatory response and disrupted alveolar histology (DAD).
Beginning of ARDS and/or
mechanical ventilation
Early exudative stage
Mechanical barrier against invading pathogens,
Sp-A and Sp-D (PRRs) production,
innate and adaptive immunity against pathogens
Adenosine converted from extracellular ATP 
Extracellular ATP
Time
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Up-regulated soluble enzymes and 
ecto-enzymes  CD39, NPP and CD73
Pro-fibrotic proteins production
(TGF-β, α-SMA, CTGF, fibronectin, bFGF, 
VEGF, insulin-like growth factor-1, etc.)
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ATP level threshold for 
P2X7R activation
Fig. 3 Putative model of local tissue purinergic signalling, pathogen
barriers, adaptive immunity and pro-fibrotic proteins during ARDS and/
or VILI [70]. In the very early phase of ARDS and VILI, infection [43,
52, 53] and vigorous mechanical deformation of the alveoli by mechan-
ical ventilation [212, 213] lead to the substantial increase of extracellular
ATP. The ATP levels exceed the threshold for the activation of P2X7R
and induce pro-inflammatory immune response [70, 211]. This causes
capillary congestion and capillary leakage causing interstitial and alveolar
oedema. CD39 expression is upregulated in severe sepsis [214] and after
several hours of mechanical ventilation [212]. Consequently, extracellular
levels of ATP gradually decrease to a certain extent and extracellular
adenosine increases. In general, adenosine has potent anti-inflammatory
properties. This may lead to immune paralysis against secondary specific
infections. Moreover, lung tissue damage due to DAD is accompanied by
the disruption of the physical barrier as a component of the innate immu-
nity for the defence against invading pathogens and by decreased Sp-A
and Sp-D levels that function as soluble pattern recognition receptors
(PRRs) of the innate immune system. This renders the host susceptible
to invading pathogens [42]. TGF-β expression is increased by the acti-
vation of P2X7Rs [175, 176] and activation of the adenosine receptor
AdoRA2B [132]. AdoRA2B activation also increases the expression of
TGF-β and other fibrotic factors such as alpha smooth muscle actin (α-
SMA), connective tissue growth factor (CTGF or CCN2), IL-6, fibronec-
tin, VEGF, CD206, arginase-1, hyaluronan, basic fibroblast growth factor
(bFGF), insulin-like factor-1, etc. (Table 3, rows 40, 44, 47 and 49) [128,
130, 132, 239]
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Conversion of extracellular ATP to adenosine
with anti-inflammatory properties.
After several hours of in vitro mechanical deformation of
Calu-3 cells (a human airway epithelial cell line that shows
cAMP-dependent Cl− secretion [223]), the messenger RNA
(mRNA) levels of CD39 and CD73 are upregulated [212].
Moreover, CD39 expression is upregulated in severe infection
such as sepsis [214]. This is probably the consequence of
increased TGF-β release due to the activation P2X7Rs by
extracellular ATP (Table 3, row 77) [175, 176] and increased
IFN-β [224–226] due to the activation of P2Y6Rs by extra-
cellular ATP as presented in Table 3 row 92 [193].
Consequently, extracellular levels of ATP gradually decrease
to a certain level, and extracellular adenosine increases. In
general, adenosine has potent anti-inflammatory properties.
Prolonged high levels of extracellular ATP lead to high levels
of extracellular adenosine and to the secondary suppression of
the innate and adaptive immune system (Fig. 3). The suppres-
sive effects of extracellular adenosine on the adaptive immune
system are presented in Table 3, rows 6–8 [81–84], 24–29
[106–112], 37 [125], 38 [126] and row 104 [206]. Note that
adenosine promotes the differentiation of naïve T cells to
CD4+FoxP3+Lag3+ Tregs [106], increases the numbers of
Tregs [112], increases the expression of the co-inhibitory sur-
face molecule CTLA-4 on Tregs [112] and upregulates the
expression of CD39 and CD73 on Tregs [112]. Tregs are
potent inhibitors of the activation and function of effector T
cells and potent inhibitors of the maturation and function of
DCs [227]. Moreover, Tregs reduce the survival of effector T
cells [227]. This causes immune paralysis against secondary
specific infections. Additionally, lung tissue damage due to
DAD is accompanied by the disruption of the physical barrier,
a component of the innate immunity for the defence against
invading pathogens and by a decrease of certain soluble PRRs
(SP-A and SP-D) production [41, 42].
Intratracheal administered ATP or UTP molecules cause
diffuse lung injury
Confirmation of the role of extracellular ATP in the pathogen-
esis of VILI is supplied by the following report by Matsuyama
et al. [213]: Intratracheally ATP or UTP (100 and 200 mM)
instilled mice showed a progressive increase in wet-to-dry
(W/D) weight ratio of the lungs during the first 18 h, the extent
of the increasedW/D ratio was dose dependent. There was also
a significant increase in the albumin permeability index. In
comparison to the reference gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), ATP induced an increase in the gene
expression (mRNA) of macrophage inflammatory protein-2
(MIP-2), TNF-α and IL-6 detected using real-time polymerase
chain reaction (RT-PCR) within 60 min after the administration
[213]. Note that the gene expression of IL-1βwas not increased
because ATP regulates the posttranscriptional activation of
NLRP3 inflammasomes [152, 228, 229], and this cannot be
detected with the applied RT-PCR technique. There was a con-
siderable rise in the number of neutrophil and macrophage
counts in the BALF. These effects appeared in intratracheally
ATP instilled mice and in mice mechanically ventilated with a
VT of 40 ml/kg ideal body weight but not with a VT of 8 ml/kg.
The ATP levels in BALF specimens in the high VT group were
significantly increased when compared to the low VT group. In
addition, the increasedW/D weight ratio, albumin permeability
and cytokine production (with the exception of TNF-α) in the
intratracheal ATP groupweremitigated by the administration of
pyridoxal-5′-phosphate-6-azophenyl-2′, 4′-disulfonic acid
(PPADS), a semi-selective antagonist of the purinergic receptor
P2X and P2Y purinergic receptors [213].
Increased extracellular ATP levels to micromolar
concentrations and conversion of very high levels
of extracellular ATP (millimolar concentrations)
to adenosine improve survival
Belete et al. applied five incremental steps of strain (0, 0.03,
0.06, 0.08, 0.10, 0.18, respectively) to experimental AT I cell
monolayers [230]. Strain was defined as the proportion of
radial length change of the monolayer during each stretch
cycle. They found that the extent of the applied cell strain
was proportional to the extracellular level of ATP and the
extent of plasma membrane damage. Adding a small amount
of ATP (10 μM) or ecto-enzyme inhibitor ARL 67156
(100 μM) decreased the proportion of the lethally wounded
AT I cells. The addition of adenosine (5 μg/ml) did not pro-
vide increased cytoprotection. The addition of apyrase (20 U/
ml) or apyrase combined with ADA (5 U/ml) to increase the
extracellular adenosine levels at the expense of the extracellu-
lar ATP levels caused an increase in the proportion of the
lethally wounded AT I cells ruling out a potential
adenosynergic cytoprotection pathway. Apparently, elevated
extracellular ATP levels to micromolar concentrations facili-
tated the plasma membrane wound healing by increasing the
fusion of the calcium-sensitive lysosomes with the plasma
membrane at the wound site. ATP induced this process in
the AT I cells in an autocrine manner through the P2Y2Rs
activating the IP3 and DAG/PKC pathways [230]. This pro-
cess is similar to the paracrine ATP-induced fusion of the LBs
with the cell membrane of the AT II cells [54, 55, 59].
Eckle et al. reported that the gene expression of the en-
zymes CD39 and CD73 that hydrolyse ATP to adenosine in
the wild-type (WT) mice lungs was increased during mechan-
ical ventilation with very high inspiratory pressure of 45 mbar
(equivalent to 45.9 cm H2O) [212]. At this inspiratory pres-
sure level, the lung volume reached TLC with a strain of 2.5
(strain was defined as the inspiratory volume divided by the
functional residual capacity) [20, 231]. In CD39−/− and in
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CD73−/− knockout mice, diffuse lung injury was far more
severe than in the WT mice [212]. Intraperitoneal administra-
tion of soluble CD39 in CD39−/− mice and soluble CD73 in
CD73−/− mice attenuated the lung injury severity to the level
of the WT mice [212]. In addition, intraperitoneal administra-
tion of soluble CD39 or CD73 in WT mice treated with the
injurious mechanical ventilation increased the survival signif-
icantly, decreased the VILI score and increased the pulmonary
adenosine levels [212]. As mentioned above, the very high
strain levels cause a massive ATP release saturating the ATP
hydrolysis enzymes CD39 and CD73 with persisting high
ATP levels. The administered soluble CD39 and CD73 con-
vert the excessive ATP molecules to adenosine causing the
inflammatory ATP levels to drop and the anti-inflammatory
adenosine levels to rise. In addition, adenosine attenuates the
ventilator-induced capillary leakage through AdoRA2B re-
ceptor signalling (Table 3, row 43) [129].
As stated earlier, the ATP hydrolysing enzymes CD39 and
CD73 are upregulated during mechanical ventilation. One of
the factors that leads to the upregulation of CD73 is the in-
creased expression of IFN-β [224–226] by the activation of
P2Y6Rs [193]. Reportedly, intravenous administration of
IFN-β-1a reduces mortality in patients with ARDS treated
with assisted mechanical ventilation significantly [232].
High levels of extracellular adenosine end in pulmonary
fibrosis
On the other hand, when the extracellular ATP levels remain
high due to continuous massive release of ATP, adenosine ac-
cumulates in the extracellular space due to the overload of the
ADA enzyme and of the re-uptake process of adenosine
through ENTs and CNTs (Fig. 2). Prolonged high levels of
extracellular adenosine result in immunosuppression, the
Fig. 4 The summary of the physiological, pathophysiological and
immunological consequences of controlled CMV with a VT ≤ 6 ml/kg
ideal body weight (left) and of controlled CMV with extremely high VT
(right) in healthy lungs (see text for explanation). The common cell
signalling pathway for the release of surfactant by alveolar epithelial
type 2 (AT II) cells and for the activation of the innate immunity (red
arrows). Sequential processes related to mechanical ventilation (grey
coloured text boxes). CMV continuous mandatory ventilation, VT tidal
volume, APRV 10% airway pressure release ventilation with the
expiration termination set at 10% of the peak-expiratory flow rate
(PEFR), DAMPs danger-associated molecular patterns, DAD diffuse al-
veolar damage
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production of fibrotic proteins and finally end in fibrosis
(Fig. 3). Reportedly, adenosine-dependent fibrosis occurs in
mice with ADA deficiency. In these mice, ADA suppletion
leads to the resolution of the fibrosis [233, 234]. On top of
the increased TGF-β expression by the activation of P2X7Rs
(Table 3, row 77) [175, 176], activation of AdoRA2B increases
the expression of TGF-β, α-SMA, connective tissue growth
factor (CTGF or CCN2), IL-6 and fibronectin in fibroblasts.
These proteins are known to be pro-fibrotic (Table 3, row 47)
(Fig. 3) [132]. One of the pro-fibrotic properties of TGF-β is
the induction of epithelial-to-mesenchymal transition (EMT), a
fundamental underlying pathogenic factor in lung fibrosis
[235]. Presumably, treatment with IFN-β-1a, with soluble
CD39 or with CD73, increases the adenosine levels. In turn,
this probably leads to a significant decrease in extracellular
ATP reducing the inflammation and the release of extracellular
ATP by the lung tissue cells and the immune cells. For a pro-
portion of patients [232] and experimental animals [212], this
may well be enough to halt the progression of DAD.
Summary and conclusion
We summarise the physiological, pathophysiological and
immunobiological consequences of controlled CMV, APRV
10% and APRV 75% in Figs. 4 and 5.
Diffuse lung tissue damage induced by systemic or local
infection, trauma or haemorrhagic shock and mechanical ven-
tilation all use a common cell signalling pathway to cause
VILI. This pathway is as follows: AT I cells are the
mechanosensors in the lung; the AT I cells secrete large quan-
tities of ATPmolecules after being infected or being vigorous-
ly stretched or compressed. This is followed by the paracrine
stimulation of AT II cells by the extracellular ATP molecules
leading to the unpacking of the LBs to the alveolar space. In
infections, many infected immune cells and tissue cells (such
as AT I and AT II cells) release ATP without requiring me-
chanical deformation of the cells.
Although increased extracellular ATP levels to micromolar
concentrations may provide cytoprotection against stretched-
Fig. 5 The summary of the physiological, pathophysiological and
immunological consequences of controlled CMV with a VT ≤ 6 ml/kg
ideal body weight or APRV 10% (left) and of APRV 75% (right) in
infected lungs (see text for explanation). The common cell signalling
pathway for the release of surfactant by alveolar epithelial type 2 (AT
II) cells and for the activation of the innate immunity (red arrows).
Sequential processes related to mechanical ventilation (grey coloured
text boxes). CMV continuous mandatory ventilation, VT tidal volume,
APRV 75% airway pressure release ventilation with the expiration
termination set at 75% of the peak-expiratory flow rate (PEFR), APRV
10% APRV with the expiration termination set at 10% of the PEFR,
DAMPs danger-associated molecular patterns, DAD diffuse alveolar
damage
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induced plasma membrane damage by the facilitation of plas-
ma membrane repair, very high levels (millimolar concentra-
tions) of extracellular ATP activate the innate immune system
by several other pathways: neutrophil recruitment and trans-
migration to the lung tissue, production of the pro-
inflammatory cytokines IL-1β and IL-18, polarization of the
macrophages towards M1 phenotype, etc. The resulting in-
flammation causes diffuse damage of the lung tissue and re-
sults in DAD. In addition, damage to the AT I and AT II cells
(due to DAD) results in a decrease in surfactant production,
extravasated serum proteins and the conversion of the active
to the non-active surfactant subfraction ending in surfactant
function impairment. The escalation of this process by venti-
lation (controlled CMVor APRV 10%) increases the extracel-
lular ATP levels and surfactant impairment even further.
Persistent release of extracellular ATP is followed by the up-
regulation of the ecto-enzymes (CD39 and CD73) decreasing
extracellular ATP levels by conversion to adenosine. High
levels of adenosine are associated with immune paralysis
against invading pathogens and progressive lung fibrosis.
When the levels of the extracellular ATP are such that treat-
ment with soluble CD39, CD73 or IFN-β is sufficient to re-
duce the pro-inflammatory response and restore the surfactant
function, VILI development will be stopped and the lungs
may recover. When the extent of lung damage is more severe
and extensive with persistent high levels of extracellular ATP,
conversion of extracellular ATP to adenosine does not lead to
the recovery of the surfactant function but instead leads to
very high levels of extracellular adenosine. In this case,
VILI will progress to the next (fibrotic) stage (Fig. 3).
Mechanical ventilation by means of controlled CMV or
APRV10%with relatively long expiration time results in cyclic
recruitment of the surfactant-deactivated alveoli causing a re-
distribution of the inspired air volume from the non-recruited
alveoli to the alveolar ducts. In addition, cyclic recruitment
leads to an increase in the volume difference between inspira-
tion and expiration in the alveolar ducts and therefore increases
the microstrain. Increased microstrain is associated with the
increase of mechanical deformation of the alveoli causing an
increase in extracellular ATP release. This ends in a vicious
circle of mechanical tissue damage → massive ATP release
→ increased inflammation → surfactant function impairment
→ exacerbating mechanical tissue damage → massive ATP
release→ etc. (Figs. 4 (right panel) and 5 (left panel)).
The essence of the prevention of VILI is to escape this
vicious circle by decreasing the extracellular levels of ATP
in the lung tissue either by the administration of IFN-β
[232], soluble CD39 and soluble CD73 [212] or by continu-
ously recruiting the alveoli until all are recruited and to keep
the recruited alveoli open [8]. This ventilator strategy prevents
the redistribution of inspired air towards the alveolar ducts,
stabilises the alveoli, minimises the microstrain and limits the
release of extracellular ATP by the cells, especially by the AT I
cells. Consequently, the innate immune response is reduced,
and the AT I, AT II cells and surfactant function are restored.
Properly set, APRV 75% appeared to do just that by opening
the lung and keeping it open, in experimental settings [7811]
and in a clinical statistical analysis [9] (Fig. 5 (right panel)).
The rationale behind the lung tissue protective effect of the
APRV 75%-induced recruitment and stabilization in
surfactant-impaired ARDS model in animals is through un-
derstanding dynamic alveolar mechanics. Alveoli are not elas-
tic (i.e. change size in a one to one relationship with the ap-
plied stress, which would be the VT); rather, alveoli are a
viscoelastic system. A viscoelastic system is represented best
by the spring and dashpot [240]. In a viscoelastic system, there
is a delay in the strain (i.e. change in alveolar size) following
the applied stress, which in the case of the lung is the
inspiratory pressure. At least two conditions have to be
fulfilled to recruit the collapsed viscoelastic alveoli: (1)
sufficiently high airway pressure of >30 cm H2O and (2)
long enough duration of the pressure (varies between 2 s
and several minutes for the individual alveolus due to the
inhomogeneous nature of the collapsed alveoli) to allow
the alveoli to be recruited [236, 237]. This is known as
the creep phenomenon of the viscoelastic system [240].
Thus, by extending the time at inspiration (i.e. increasing
the duration of the applied stress), we gradually ‘nudge’
alveoli open over time [236]. Fully recruiting the lung
eliminates stress concentrators, a major VILI mechanism
[238]. The lung is stabilised by a very short time at expi-
ration. If the stress (i.e. inspiratory pressure) is released
very quickly for a very short time, the viscoelastic alveoli
will not have time to empty, maintaining a PEEP. Thus,
the short expiratory duration stabilises the lung by two
mechanisms: time and pressure. Using our understanding
of dynamic alveolar mechanics and the fact that alveoli
are viscoelastic, we use the MBP parameter of duration to
open and stabilise the lung. Using a short expiratory du-
ration stabilises alveoli and prevents the redistribution of
the inspired air towards the alveolar ducts and prevents
vigorous cyclic deformation of the alveoli [8], which, in
turn, prevents massive extracellular ATP release, massive
short-term surfactant release, followed by surfactant function
impairment, interstitial and alveolar oedema and activation of
the innate immunity leading to the development or aggrava-
tion of DAD. This presumably prevents the loss of AT I cells,
prevents the hyperplasia of AT II cells and restores the surfac-
tant function, and the affected lung regions start to regain their
normal compliance (increase their alveolar time constant).
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